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Abstract 
 
Objective: Mechanisms responsible for osteoarthritic pain remain poorly understood and current 
analgesic therapies are often insufficient. We have characterized and pharmacologically tested the 
pain phenotype of a non-invasive mechanical joint loading (MJL) model of osteoarthritis thus 
providing an alternative murine model for osteoarthritic pain. 
 
Methods: The right knees of male mice (12-week-old, C57BL/6) were loaded at 9N or 11N (40 cycles, 
three times/week for two weeks). Behavioural measurements of limb disuse, mechanical and 
thermal hypersensitivity were acquired before MJL and monitored for six weeks post-loading. The 
severity of articular cartilage lesions was determined post-mortem with the OARSI grading scheme. 
Furthermore, 9N-loaded mice were treated for four weeks with diclofenac (10mg/kg), gabapentin 
(100mg/kg) or anti-Nerve Growth Factor (3mg/kg).  
 
Results: Mechanical hypersensitivity and weight-bearing worsened significantly in 9N- and 11N-
loaded mice two weeks post-loading compared to baseline values and non-loaded controls. 
Maximum OA scores of ipsilateral knees confirmed increased cartilage lesions in 9N- (2.8±0.2) and 
11N-loaded (5.3±0.3) mice compared to non-loaded controls (1.0±0.0). Gabapentin and diclofenac 
restored pain behaviours to baseline values after two weeks of daily treatment, with gabapentin 
being more effective than diclofenac. A single injection of anti-NGF alleviated nociception two days 
after treatment and remained effective for two weeks with a second dose inducing stronger and 
more prolonged analgesia. 
 
Conclusion: Our results show that MJL induces OA lesions and a robust pain phenotype that can be 
reversed using analgesics known to alleviate OA pain in patients. This establishes the use of MJL as 
an alternative model for osteoarthritic pain. 
 
Introduction  
 
Osteoarthritis (OA) is a common degenerative joint disease associated with chronic, 
debilitating pain in the affected joints which significantly reduces the mobility and quality of life in 
patients [1]. Current therapies used to treat OA pain are often insufficient, with Non-Steroidal Anti-
Inflammatory Drugs (NSAIDs) producing unwanted side effects which limit long-term use [2]. OA 
pathology and progression have been examined in detail, however, mechanisms contributing to 
osteoarthritic pain and the relationship between pain and OA pathology remain poorly understood. 
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To address this there is a need for a well characterized, non-invasive murine model of OA pain which 
exhibits both a robust, reproducible pain phenotype and histological evidence of OA pathology.  
The two most commonly used models of OA in the preclinical field of osteoarthritic pain are 
the monosodium iodoacetate (MIA) model used to induce inflammatory OA [3] and surgical 
destabilization of the joint typically used to model post-traumatic OA [4, 5]. In the MIA model, a 
single intra-articular injection of MIA is placed in the knee joint which inhibits the glycolytic pathway 
causing chondrocytic cell death and an acute inflammation leading to cartilage erosion and joint 
disruption [6, 7]. The MIA injection causes immediate onset of mechanical hyperalgesia [8, 9], 
altered weight-bearing [10] and reduction in mobility [11] which are associated with the early, 
inflammatory phase (day 0-7). This is then followed by a more persistent allodynia typical for late 
phase OA (day 14-28). Pain-like behaviours increase in a dose-dependent manner, with late phase 
hypersensitivity typically observed at higher doses of MIA [12]. Surgical models, like the 
destabilization of the medial meniscus (DMM) [4] or the partial medial meniscectomy (PMM) [5, 13], 
are used predominantly in mice and rely on the surgical destabilization of the medial meniscus which 
typically leads to cartilage damage 4 to 8 weeks post-surgery [5, 14, 15]. Pain-like behaviours 
typically take longer to develop with mechanical hypersensitivity developing 4 weeks post-surgery, a 
decrease in spontaneous naturalistic behaviours seen 8 weeks post-surgery and an altered weight-
bearing observed as late as 12 weeks post-surgery [13, 16, 17]. Mice undergoing sham surgery also 
show significant amounts of post-surgical pain [16, 17], with pain thresholds taking as long as 8 
weeks to return to baseline levels [18]. A major drawback of both models is the invasiveness of the 
procedures which adds a layer of joint disruption that influences both joint damage and the resulting 
pain behaviours in affected as well as sham animals.  
The non-invasive mechanical joint loading (MJL) model was initially used to investigate the 
osteogenic effect of mechanical loading on bone [19] and has recently been adapted to investigate 
the pathogeneses of OA [20]. The model induces OA through intermittent, repetitive loading of the 
tibia through the knee and ankle joints. Histological cartilage changes have been characterized in 
mice and show that single loading episodes induce lesions in the articular cartilage [20]. When 
loading episodes are repeated three times per week for two weeks these lesions spontaneously 
progress and worsen over a time frame of three weeks [20]. This model also shows changes in the 
subchondral bone [21] consistent with pathology seen in humans. This recent use of MJL as a model 
of OA means that the pain phenotype in this model has not yet been fully characterized. 
The aim of this study was to characterize the pain phenotype of the murine MJL model of OA 
to determine if it can be used as a model of osteoarthritic pain. To this end we induced OA of 
different severity using two different load magnitudes and monitored hypersensitivity thresholds 
over time using an array of established behavioural assays developed in mice [22]. The presence of 
OA knee pathology was confirmed at the end of the study by quantifying cartilage damage. 
Furthermore, we investigated whether diclofenac, gabapentin or anti-Nerve Growth Factor 
monoclonal antibody (anti-NGF mAb) could alleviate the OA pain seen in this model. Diclofenac is an 
NSAID effective against inflammatory pain and the first-line treatment in the clinic for patients with 
OA pain [23] whilst gabapentin is an antiepileptic drug that is effective in complex neuropathic pain 
syndromes [24, 25]. Anti-NGF antibodies represent novel analgesics currently in clinical trials for OA 
pain [26-28]. In vivo studies show that anti-NGF treatment restores spontaneous day/night activity in 
mice with orthopaedic surgery-induced pain [29] and improves gait imbalance in both the MIA 
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model [30] and surgical model of OA [31]. Additionally, treatment with the soluble NGF receptor, 
TrkAD5, effectively restored the altered weight-bearing seen directly after DMM surgery (post-
operative pain) as well as 16 days post-surgery (OA pain) [32]. Testing the efficacy of these drugs in 
alleviating pain is the first step in validating the MJL as an appropriate model for osteoarthritic pain.  
 
Methods 
 
Animals 
 
Naïve male 10-week-old C57BL/6 mice (Charles River) were housed in groups of four in 
individually ventilated cages and fed a standard RM1 maintenance diet ad libitum. The environment 
was climate and light controlled; temperature 22°C, humidity 50%, lights on from 7AM-7PM. Animals 
were acclimatized for one week before start of procedures which were conducted during the light 
phase (8AM-6PM). All experiments were carried out in compliance with the Animals (Scientific 
Procedures) Act (1986) and approved by the UK Home Office license.  
 
In vivo mechanical joint loading 
 
Osteoarthritis was induced in mice by a two week loading regime [20] using an electronic 
materials testing machine (Bose 3100). Mice were 12 weeks old at the start of loading which was 
performed under general anaesthesia (3.5% isoflurane). The right tibia was positioned vertically 
between two custom-made loading cups which restrict the knee and ankle joints in deep flexion. 
Axial compressive loads were applied through the knee joint via the upper loading cup whilst a 
loading cell, attached to the lower cup, registered and monitored the applied loads. One loading 
cycle consists of 9.9 seconds holding time with a load magnitude of 2N (load needed to maintain 
knee position) after which a peak load of 9N or 11N was applied for 0.05 seconds with a rise and fall 
time of 0.025 seconds each. This 10 second trapezoidal wave loading cycle was repeated 40 times 
within one loading episode. During the loading regime this loading episode was repeated three times 
per week for two consecutive weeks. The load magnitudes of 9N or 11N were chosen to enable 
comparisons with previously published work on the loading model [19-21].   
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Experimental design 
 
Pain phenotype after mechanical joint loading 
Mice loaded at 9N or 11N (n = 8 / group) underwent behavioural measurements (see 
supplementary methods for overview) at baseline in the week before loading and were monitored 
weekly for six weeks post-loading. Changes in behaviour were compared to age and cage matched, 
non-loaded controls which were not subjected to any loading regime but instead underwent 
isoflurane anaesthesia for the same duration as loaded mice. No behavioural testing was performed 
during the two weeks of loading.  
 
Pharmacological validation of mechanical joint loading   
The MJL model was validated by testing the anti-nociceptive effect of diclofenac, gabapentin 
and an anti-NGF mAb on 9N-loaded mice. In total six groups (n = 8/group) were tested; three 
experimental groups in which one dose of each drug was tested and three control groups; non-
loaded saline-treated, loaded saline-treated and loaded inactive control antibody treated. Analgesic 
treatment was administered from two to six weeks post-loading. Animals receiving diclofenac (10 
mg/kg, p.o. [33], Sigma-Aldrich), gabapentin (100 mg/kg, p.o. [33], Sigma-Aldrich) or saline (0.9% 
NaCl, p.o., Sigma-Aldrich) were treated daily via gavage without anaesthesia. The volume 
administered was calculated according to the weight of the animal (<500µL). Anti-NGF mAb 
treatment (3 mg/kg, i.p., MEDI578 Batch: SP10-291, generously gifted by AstraZeneca, MedImmune) 
was administered at weeks two and four post-loading. Loaded controls received the inactive 
antibody (3 mg/kg, i.p., NIP228 IgG4P control Batch: SP-15-302, AstraZeneca, MedImmune) at same 
time-points.  
Pain thresholds were measured at baseline and continued after loading on a weekly basis in 
mice receiving saline, diclofenac or gabapentin. Behavioural testing started one hour after 
treatment. Animals receiving anti-NGF or inactive antibody were tested 4, 24 and 48 hours and then 
every two days following treatment.  
 
Histological analysis of joints and OA grading 
 
 Six weeks post-loading, mice were euthanized by CO2 overdose followed by cervical 
dislocation. Hind limbs were removed and fixed in 4% neutral buffered formalin for 48 hours. Knees 
were then decalcified (Immunocal, Quartett) for 5 days and processed for paraffin embedding. Once 
embedded, 6µm coronal sequential sections were acquired of the entire joint, of which a quarter 
was stained with toluidine blue (0.1% in 0.1M acetate buffer, pH 5.6). OA severity was scored for 
each stained section using a grading system [34] ranging from 0-6. Briefly, grade 0 corresponds to 
normal surface articular cartilage; grade 0.5, a loss of toluidine blue staining; grade 1, lesions in the 
superficial zone of the articular cartilage; grade 2, lesions down to the intermediate zone; grade 3, 
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lesions down to the tidemark with possible loss of articular cartilage up to 20% of the surface of the 
condyle; grade 4, loss of 20% to 50% articular cartilage; grade 5 loss of 50-80% of articular cartilage; 
and finally, grade 6, with above 80% articular cartilage loss and exposure of subchondral bone. For 
each knee the maximum OA score, as determined by the lesion with the highest severity, and a 
summed OA score is reported. OA severity is classified as either low (grade 0-2), mild (grade 3-4) or 
severe (grade 5-6). 
 
Statistical analysis 
 
Data were analysed using GraphPad Prism (7.04). Results are presented as mean ± SEM. 
Mice were assigned conditions in a pseudo-random order, ensuring comparable behavioural 
baseline values and allocating different conditions within the home cage. Two mice in the diclofenac 
treatment group were excluded from analysis due to adverse gastro-intestinal effects. After checking 
for normal distribution, multiple groups were compared using parametric two-way ANOVA followed 
by a Bonferroni post hoc test. Values of p less than 0.05 were considered as statistically significant.  
 
Results 
 
MJL at both 9N and 11N induces chronic mechanical hypersensitivity combined with altered 
weight-bearing and reduced mobility.  
 
MJL with a load of either 9N or 11N induces a mechanical pain phenotype which is 
established two weeks post-loading and progressively worsens until six weeks post-loading. From 
two to six weeks post-loading, 9N- (figure 1A) and 11N-loaded (figure 1C) mice show a significant 
and persisting reduction in mechanical sensitivity compared to both baseline values and non-loaded 
controls (for 9N- and 11N-loaded mice; p<0.001). Mice loaded at 9N show a reduction from baseline 
(0.513g±0.06g) to two weeks post loading (0.207g±0.04g) with thresholds progressively lowering 
further till 6 weeks post-loading (0.131g±0.03g). 11N-loaded mice show a similar trend with baseline 
mechanical threshold (0.505g±0.08g) dropping 2 weeks post-loading (0.165g±0.03g) and stabilizing 
up to 6 weeks post-loading (0.108g±0.03g). Notably, there is also a reduction in the mechanical 
sensitivity thresholds of the contralateral paw, although this develops at a later stage and is not as 
pronounced as in the ipsilateral paw (figure 1B and D, respectively).  
The development of mechanical hypersensitivity was accompanied by altered weight-
bearing and reduction in mobility. 9N-loaded mice progressively reduced the percentage of weight 
borne on the ipsilateral hind limb from baseline (49.94%±0.6%) to 4 weeks post-loading 
(44.15%±1.4%) which is significantly different to weight-bearing values in non-loaded controls 
(p=0.0024, figure 2A). Mice loaded at 11N also showed a decrease in ipsilateral weight-bearing over 
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time significantly different to non-loaded controls (p=0.0343, figure 2C); with values decreasing from 
baseline (49.41%±0.3%) to 2 weeks post-loading (41.03%±2.5%) but then returning 4 weeks post-
loading (47.67%±1.5%) to finally decrease again at 6 weeks post-loading (44.23%±2.1%.).  
Motor ability was slightly reduced in the 9N-loaded mice which showed a decline in time 
spent on the rotarod compared to non-loaded control mice (p=0.0238). This reached significance at 
six weeks post-loading (figure 2B). 11N-loaded mice exhibit a similar decline in time spent on the 
rotarod which is significance 5 weeks post-loading (p=0.0071, figure 2D).  
Thermal sensitivity as determined by the hot plate (50⁰C and 55⁰C), cold plate (0⁰C), 
Hargreaves and cold plantar assay measurements showed no difference in thresholds between 
loaded and non-loaded animals (results not shown). The non-loaded control group did not show 
changes over time in any of the pain measurements.  
 
MJL at both 9N and 11N induces articular cartilage lesions. 
 
Histological analysis of joints revealed that loading at both 9N and 11N induced OA lesions in 
ipsilateral and contralateral knees, with higher maximum (figure 3A) and summed (figure 3B) 
severity scores compared to the non-loaded controls. Maximum ipsilateral articular cartilage lesions 
were higher in 11N-loaded mice (5.3±0.3) compared to 9N-loaded mice (2.8±0.2, p<0.001, figures 
3C-H). The development of lesions seen in 9N-loaded mice at one, three and six weeks post-loading 
is shown in the supplementary data. Additionally, the contralateral knees showed mild OA lesions in 
both 9N (1.8±0.2) and 11N-loaded (2.1±0.5) mice. The extreme OA pathology seen in 11N-loaded 
mice compared to that seen in the 9N-loaded mice led to a 9N loading regime to be used in the 
pharmacological study.   
 
Treatment with diclofenac, gabapentin and anti-NGF mAb at two weeks post-loading relieves the 
mechanical hypersensitivity and improves the weight distribution without affecting motor ability. 
 
For the pharmacological validation of the MJL model all animals were loaded at 9N. The non-
loaded, saline-treated animals showed no change in nociceptive thresholds over time whilst the 
loaded saline-treated group exhibited mechanical hypersensitivity and altered weight-bearing from 
2 weeks post-loading as previously shown (figure 4). Both gabapentin and diclofenac relieved the 
mechanical hypersensitivity (figure 4A) and the altered weight-bearing (figure 4B) after two weeks of 
treatment, with gabapentin being more effective than diclofenac. Two weeks of gabapentin 
treatment increased the mechanical threshold (1.234g±0.11g) compared to that before treatment 
(0.148g±0.03g), making mechanical sensitivity significantly higher compared to loaded, saline-
treated mice, (p<0.001, figure 4A). In comparison, diclofenac increased mechanical thresholds 
(0.083g±0.02g) after two weeks of treatment (0.472g±0.09g, p=0.0057 when compared to loaded, 
saline-treated mice, figure 4A). Both gabapentin and diclofenac effectively reversed the altered 
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weight-bearing after two weeks of treatment; gabapentin (46.62%±3.0%) and diclofenac 
(47.23%±2.1%) compared to loaded, saline-treated mice (39.91%±2.1%, figure 4B).  
The first injection of anti-NGF antibody effectively alleviated loading-induced pain 
behaviours (figure 5), with the second injection showing a stronger and more prolonged analgesic 
effect. Two days after the first treatment, the anti-NGF mAb significantly alleviated mechanical 
hypersensitivity (0.360g±0.08g) compared to inactive antibody-treated animals (0.117g±0.02g, 
p=0.028). This lasted for four days after which the effect dwindled. The second treatment with anti-
NGF mAb was also effective two days post-injection inducing a cumulative effect with mechanical 
sensitivity returning to and exceeding baseline values (0.820g±0.10g), compared to animals treated 
with inactive antibody (0.072g±0.01g, p<0.001). Effectiveness of the second anti-NGF mAb 
treatment lasted up to 13 days post-injection (figure 5A). Weight-bearing results show a similar 
pattern with anti-NGF mAb treatment restoring weight-distribution one week post-injection but 
losing effectiveness two weeks later (figure 5B). A week after the second anti-NGF mAb treatment, 
animals showed significantly improved weight-bearing (51.44%±1.9%) compared to animals treated 
with inactive antibody (38.76%±1.0%, p<0.001, figure 5B). 
All treatment groups showed a similar decline mobility, as measured by the rotarod, 
compared to loaded controls (saline-treated; figure 6A or inactive antibody treated; figure 6B), 
except for diclofenac-treated animals which did not show a decrease in time spent on the rotarod 
(figure 6A). Furthermore, exploratory behaviour was the same in all groups (figure 6C) and none of 
the treatments influenced weight gain (data not shown).  
 
Discussion 
 
In this study, we demonstrate that mechanical joint loading (MJL) is an appropriate model to 
specifically study mechanically-induced osteoarthritic pain. We have characterized the symptomatic 
aspects of mechanically-induced osteoarthritis by measuring the development of nociceptive 
behaviour alongside a histopathological presence of OA. Furthermore, the first step was taken in 
validating the MJL model by showing alleviation of nociceptive behaviour when treated with 
different classes of analgesics.   
Mechanical loading of joints is known to induce alterations in articular cartilage [35] which, 
in cases of repetitive or excessive loading, can lead to osteoarthritis [36]. The MJL model has been 
developed to explore the mechanisms responsible for mechanically-induced osteoarthritis [20]. It 
mimics structural changes typically seen in human OA such as spontaneously progressing articular 
cartilage lesions, subchondral bone changes and osteophyte formation [20, 21]. The non-invasive 
nature of this model has an added value of enabling examination of whole joint pathology in an 
intact knee. This avoids complications typical for surgical interventions, like post-surgery pain and 
infection risk, thus increasing animal welfare and reducing variance in behavioural measurements.  
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 This is the first measurement of pain behaviours in this model. MJL at both 9N and 11N 
induces mechanical hypersensitivity accompanied by altered weight-bearing and reduced mobility, 
without affecting thermal sensitivity. The development of pain-like behaviours is comparable for 
both loading intensities, with ipsilateral mechanical hypersensitivity and altered weight-bearing 
developing from two weeks post-loading and contralateral mechanical hypersensitivity, as well as 
reduced mobility, developing 4-5 weeks post-loading. This pain phenotype is similar to the pain 
observed in OA patients that initially presents with hypersensitivity of the affected joint and pain 
during weight-bearing. Frequency, duration and severity of pain worsen as OA progresses and 
peripheral as well as central neurological mechanisms are recruited, which leads to centralized 
allodynia common for late stage OA [37]. Consequently, the contralateral mechanical 
hypersensitivity observed after MJL could be due to altered gait [21] where mice relieve ipsilateral 
hypersensitivity by compensating with their contralateral limb or, alternatively, it could indicate a 
centralized hypersensitivity. No significant changes in behavioural measurements were observed in 
the first week after loading which suggesting that progressive mechano-adaptive changes over time, 
rather than the initial insult of mechanical loading, are responsible for the nociceptive behaviour. 
Further studies show that the initial cartilage lesions induced by MJL at 9N worsen over time, 
matching the progressive nature in the development of nociceptive behaviour (see supplementary 
data). Taken together these results suggest that MJL induces a nociceptive phenotype typical for 
progressive, mechanically induced OA.  
 This nociceptive phenotype seen after MJL, is more comparable with surgical models of OA 
than with the MIA model. The MIA model typically shows a stark increase in mechanical 
hypersensitivity and altered weight-bearing immediately after injection which persists up to 28 days 
post injection [8, 12, 38] whereas the MJL model does not show this immediate nociceptive 
response typical of the inflammatory form of OA seen in the MIA model. Furthermore, MIA 
injections in mice do not induce a reduction in motor ability [12, 38], or any contralateral nociceptive 
behaiour. In the DMM model mechanical hypersensitivity develops 2-4 weeks post-surgery and lasts 
up to 16 weeks [18], with altered weight-bearing taking up to 12 weeks to develop [16] and no 
change in locomotion or thermal sensitivity [39]. Although the onset of nociceptive behaviours 
appears earlier in the MJL model, the delay in behavioural responses seen in both MJL and DMM 
models is common for a progressive form of OA. Additionally, DMM induces contralateral 
nociceptive behaviours [39] comparable to those seen in the MJL model, indicating compensatory 
behaviour or central hypersensitization. In contrast, the MJL model does not show any post-surgical 
pain or hypersensitivity in sham animals that is typical for surgical models [5, 17]. Rather than relying 
on inflammatory damage of the joint as shown in the MIA model, both the MJL and the DMM 
models rely on a mechanical disruption and joint destabilization similar to that seen in human OA 
where excessive use or trauma leads to progressive joint damage.  
A general drawback of this model is that there is no sham procedure which can control for, 
or rule out, off target damage induced by the loading procedure. The non-loaded controls used do 
not get loaded but are subjected to the anaesthesia procedure and, consequently, function as 
behavioural controls rather than controls for knee pathologies not related to mechanically-induced 
OA. Mice loaded statically at 2N (data not shown) show mild ipsilateral mechanical hypersensitivity 
which is neither consistent nor progressive. Additionally, these mice exhibit mild ipsilateral lesions in 
the articular cartilage. This makes the 2N-loaded mice inappropriate as controls for osteoarthritic 
pain. 
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At six weeks post-loading, both 9N- and 11N-loaded mice show lesions in the articular 
cartilage of ipsilateral and contralateral knees, confirming that MJL induces an OA-like 
histopathological phenotype. Analysis of articular cartilage lesions at one, three and six weeks post-
loading at 9N (supplementary data) show that lesions in this study are comparable to those 
described by Poulet et al. [20] 3 weeks post-loading in mice with the same loading regime. 
Additionally, these results confirm the spontaneous exacerbation of lesions at 3 weeks post-loading 
compared to lesions seen directly after loading. The time frame in which these lesions progress and 
worsen corresponds to the development of nociceptive behaviours in this model, suggesting that the 
progressive degradation of the knee induces this behaviour. Furthermore, both 9N- and 11N-loaded 
mice showed mild contralateral damage which could explain the development of contralateral 
mechanical hypersensitivity seen in these animals.  
Notably, 11N-loaded mice had extensive ipsilateral damage, with lesions consistently 
reaching maximum scores, whilst 9N-loaded mice showed milder OA histopathology without 
heightened nociceptive behaviour. This implies that, although cartilage damage is an important 
indicator of OA, it does not necessarily relate to the severity of pain. Pro-osteogenic changes in the 
tibia, for which this model was originally developed, are typically only seen at loading magnitudes of 
13N or higher [19]. With the loading regimes of 9N or 11N no such osteogenic effects were observed 
(data not shown), indicating that bone remodelling of the tibia does not contribute to the MJL-
induced development of nociceptive behaviour. Knee OA is a whole joint disease and, in patients 
with OA, moderate correlations between pain severity and MRI or radiograph read-outs of tissue 
damage have been shown for a variety of knee tissues including joint space narrowing [40], 
subchondral bone changes, synovitis and meniscal tears [41]. Additional experiments will be needed 
to study the effect of MJL on other joint tissues and identify their role in the development of 
nociceptive behaviour. The lack of difference in pain profile seen between the 9N- and 11N-loaded 
mice could reflect the modest sensitivity of pain read-outs used, all of which are measurements for 
referred pain. However, results from this study clearly show that 11N-loaded mice develop the 
maximum possible knee damage, thus reaching a ceiling effect in both OA severity score and pain 
phenotype. The severe knee pathology seen in these mice could indicate that MJL at 11N induces 
damage which is not restricted to the cartilage but also affects other joint tissues. Combined with 
the observation that the 9N-loaded mice develop a milder form of OA but still show a robust pain 
phenotype it was concluded that loading regime at 9N was more appropriate for follow-up 
pharmacology studies.  
Diclofenac, gabapentin and anti-NGF mAb, all analgesics used treat OA pain in patients, were 
effective in alleviating MJL-induced nociceptive behaviour. Additionally, these treatments had no 
effect on the exploratory behaviour or weight of the mice demonstrating that animal welfare was 
not compromised. We also showed that none of these treatments compromised mobility, suggesting 
that the restoration of behavioural responses to baseline values was due to their analgesic effects 
rather than possible sedative side effects or motor impairment. 
In the first two weeks of treatment, gabapentin was more effective in alleviating mechanical 
hypersensitivity and restoring weight-bearing than diclofenac. This is particularly striking considering 
that diclofenac, which is typically effective in treating inflammatory pain, is the first line treatment 
for OA whilst gabapentin is more commonly used to treat neuropathic pain. Despite the preferential 
effectiveness against neuropathic pain, gabapentin has been shown to be effective in treating 
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nociception in both MIA [42] and surgical models [43, 44] of OA. The efficacy of gabapentin in 
several OA pain models suggests that OA pain could in part be of neuropathic origin. In fact, in the 
PMM model of OA, diclofenac was only effective in treating nociception in the initial inflammatory 
phase but not at a later stage, whereas gabapentin alleviated the mechanical hypersensitivity seen in 
the chronic phase of OA-induced nociception [5]. Taken together, this suggests that although 
inflammation and the resulting pain do likely play a role in OA pathology, OA is a complex pain 
syndrome with a significant neuropathic component. 
The anti-NGF antibody showed a prolonged and significant reduction in nociceptive 
hypersensitivity with repeated treatment increasing the magnitude and duration of its effectiveness. 
There is a lot of evidence supporting a role for NGF in osteoarthritic pain [45]. Chondrocytes produce 
NGF in response to degeneration, NGF levels are elevated in the synovial fluid of patients with OA 
and in clinical trials anti-NGF mAb treatment has provided significant pain relief in OA patients [46]. 
Furthermore, in the MIA and medial meniscal transection murine models of OA, intra-articular 
injections of NGF increased nociceptive behavioural responses in both experimental and healthy 
control animals suggesting that NGF plays a role in the severity of OA pain [47]. The prolonged 
effectiveness of anti-NGF mAb treatment in the MJL model is similar to the MIA model where anti-
NGF effectively restored altered gait for up to 35 days post treatment [30, 48].  
Historically, several murine models of OA have been useful in unravelling mechanisms of 
pathogenesis of this condition. The ease of genetic modification, the relative low costs and reduced 
time needed for disease progression make mice widely used in both OA and pain research. Here we 
present an alternative model that closely mimics an OA phenotype typical for mechanically-induced 
OA. Our results show that the non-invasive mechancial joint loading model induces both OA lesions 
and a reproducible pain phenotype which can be reversed using known analgesics for OA pain, thus 
suggesting its use as an alternative model to study osteoarthritic pain. 
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Figure Legends 
 
Figure 1: Development of mechanical hypersensitivity after MJL.  
The right knees of mice were loaded three times per week for two weeks at 9N (red line, n = 8) or 
11N (green line, n = 8) to induce OA. Development of mechanical hypersensitivity was measured 
using von Frey filaments (50% paw withdrawal threshold (PWT) in grams) in the ipsilateral (A, 9N and 
C, 11N) and contralateral paws (B, 9N and D, 11N). The values were compared to a non-loaded 
isoflurane control (black dotted line, n = 8). Significant changes between non-loaded and loaded 
animals are indicated with a # (p < 0.05), ## (p < 0.01) or ### (p < 0.001) whilst significant changes 
within groups over time (compared to baseline value) are indicated with a * (p < 0.05), ** (p < 0.01) 
or *** (p < 0.001). Values given as the mean ± SEM 
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Figure 2: Altered weight-bearing and reduced mobility after MJL.  
The right knees of mice were loaded three times per week for two weeks at 9N (red line, n = 8) or 
11N (green line, n = 8) to induce OA. Altered weight-bearing (weight placed on ipsilateral paw as a 
percentage of total weight placed on both legs) was measured using the incapacitance test (A, 9N 
and C, 11N). Motor ability was measured using the rotarod (duration mice were able to remain on 
the rotarod; B, 9N and D, 11N). The values were compared to a non-loaded isoflurane control (black 
dotted line, n = 8). Significant changes between non-loaded and loaded animals are indicated with a 
# (p < 0.05), ## (p < 0.01) or ### (p < 0.001) whilst significant changes within groups over time 
(compared to baseline value) are indicated with a * (p < 0.05) or ** (p < 0.01). Values given as mean 
± SEM 
 
Figure 3:  Severity of OA lesions after MJL at 9N and 11N.  
Ipsilateral and contralateral knees of non-loaded and loaded mice at 9N and 11N were collected post 
mortem at 6 weeks post-loading and OA severity was scored (scoring system from 0-6, OA severity is 
classified as either low (grade 0-2), mild (grade 3-4) or severe (grade 5-6)). Maximum OA scores (A) 
and summed OA scores (B) are given for non-loaded (black circles, n = 6), 9N-loaded mice (red 
squares, n = 6) and 11N- loaded mice (green triangles, n = 6). Significant differences in the severity of 
OA lesions indicated with a # (p < 0.05), ## (p < 0.01) or ### (p < 0.001). Values given as mean ± SEM. 
Examples of typical knee histology of the ipsilateral knee are shown for non-loaded (C and D), 9N-
loaded (E and F) and 11N-loaded mice (G and H), with panels B, D and F showing whole knee joint 
and panels C, E and G showing the medial compartment at 10x magnification. Arrows indicate typical 
cartilage damage seen for each condition.  
 
Figure 4: Effect of diclofenac and gabapentin treatment on post-loading mechanical 
hypersensitivity and altered weight-bearing. 
Daily analgesic treatments were started two weeks post-loading indicated with grey, dotted line. 
Mechanical hypersensitivity (A, 50% paw withdrawal threshold (PWT) in grams) and weight-bearing  
(B, weight placed on ipsilateral paw as a percentage of total weight placed on both legs) was 
monitored on a weekly basis for animals receiving saline (non-loaded controls; black dotted line, and 
9N-loaded controls; red line, n = 8), diclofenac (10 mg/kg p.o., green line, n = 6) or gabapentin (100 
mg/kg p.o., blue line, n = 8) treatment. Significant changes between treated and saline-treated 9N-
loaded groups are indicated with a $ (p < 0.05), $$ (p < 0.05) or $$$ (p < 0.05) whilst significant 
changes within groups over time (compared to baseline value) are indicated with a * (p <0 .05), or 
*** (p < 0.001) in corresponding colours. Values given as the mean ± SEM 
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Figure 5: Effect of anti-NGF mAb treatment on post-loading mechanical hypersensitivity and 
altered weight-bearing.  
Animals received anti-NGF mAb treatment two and four weeks post-loading, indicated in both cases 
with grey dotted lines. Mechanical hypersensitivity was initially monitored on a weekly basis and 
then on a more frequent basis after animals started receiving anti-NGF (MEDI578, 3 mg/kg i.p., black 
line, n = 8) or inactive antibody (NIP228, 3 mg/kg i.p., red dotted line, n = 8) treatment. Panel A; 50% 
paw withdrawal threshold (PWT) in grams and behavioural days indicated in blue as number of days 
post-treatment. Weight-bearing was monitored on a weekly basis (B; weight placed on ipsilateral 
paw as a percentage of total weight placed on both legs).  Significant changes between treated 
groups and saline treated 9N-loaded groups are indicated with a $ (p < 0.05) or $$$ (p < 0.05) whilst 
significant changes within groups over time (compared to baseline value) are indicated with a * (p <0 
.05), ** (p < 0.01) or *** (p < 0.001) in corresponding colours. Values given as the mean ± SEM 
 
Figure 6: Effect of analgesic treatment on post-loading motor ability and natural exploratory 
behaviour.  
Motor activity was assessed by the rotarod (duration mice were able to remain on rotaod in 
seconds). Panel A shows controls animals receiving saline (non-loaded controls; black dotted line, n = 
8 and 9N-loaded controls; red line, n = 8), diclofenac (10 mg/kg p.o., green line, n = 6) or gabapentin 
(100 mg/kg p.o., blue line, n = 8) treatment and panel B shows animals receiving anti-NGF (MEDI578, 
3 mg/kg i.p., black line, n = 8) or inactive antibody (NIP228, 3 mg/kg i.p., red dotted line, n = 8) 
treatment. Significant changes within groups compared to baseline values are indicated with a * (p < 
0.05) or *** (p < 0.001) in corresponding colours. Natural exploratory behaviour as measured with 
the open field was also unaffected by treatment as shown in panel C (of crossing in the open field 
over 5 minutes). Values given as mean ± SEM  
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